Your AI-Trained Oncology Knowledge Connection!
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of CPX-351, a fixed-combination of daunorubicin and cytarabine, for adult patients with newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab (Opdivo) as an adjuvant treatment for adult patients with completely resected melanoma with lymph node involvement or metastatic disease
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of tisagenlecleucel for the treatment of either adult patients with diffuse large B-cell lymphoma that is relapsed or refractory after 2 or more lines of systemic therapy, or patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse posttransplant, or in second or later relapse.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of neratinib for the extended adjuvant treatment of adult patients with early stage hormone receptor–positive, HER2-overexpressed/amplified breast cancer following postoperative trastuzumab.
Lyudmila A. Bazhenova, MD, discusses treatments for patients with ALK-positive NSCLC, as well as the progress in less common oncogenic drivers, such as NTRK fusions.
European patients with non-Hodgkin lymphoma are more likely to be prescribed a rituximab biosimilar if they are in better overall health, have indolent histology, and have follicular lymphoma.
Mitesh J. Borad, MD, discusses liver-directed therapies, systemic therapy, and the management of liver cancer.
Kathryn A. Gold, MD, discusses the evolving management of EGFR-mutant non–small cell lung cancer and the latest developments in small cell lung cancer.
The FDA has granted a priority review to a new drug application for glasdegib for use in combination with chemotherapy for the frontline treatment of patients with acute myeloid leukemia.
The FDA has approved the combination of the BRAF inhibitor encorafenib (Braftovi) and the MEK inhibitor binimetinib (Mektovi) for the treatment of patients with BRAF-mutant unresectable or metastatic melanoma, as detected by an FDA-approved test.
Olaparib tablets reduced the risk of disease progression or death compared with placebo as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase III SOLO-1 trial.
Ramesh K. Ramanathan, MD, discusses sequencing strategies and emerging therapeutic targets in pancreatic cancer.
Axel Grothey, MD, discusses sidedness and first- and second-line treatments for patients with metastatic colorectal cancer.
Treatment with the recombinant oncolytic poliovirus PVSRIPO elicited sustained a 2- and 3-year overall survival (OS) rate of 21% (95% CI, 11%-33%) for patients with recurrent grade IV malignant glioblastoma.
Patients with metastatic colorectal cancer who are not eligible for chemotherapy or surgical resection may have a new first-line treatment option.
The combination of palbociclib (Ibrance) and fulvestrant (Faslodex) failed to improve overall survival compared with fulvestrant and placebo in the phase III PALOMA-3 trial for patients with HR-positive, HER2-negative metastatic breast cancer.
Combining frontline atezolizumab with chemotherapy improved overall survival and progression-free survival compared with chemotherapy alone in patients with extensive-stage small cell lung cancer.
The FDA has accepted a supplemental biologics license application for the use of pembrolizumab as an adjuvant treatment for patients with resected, high-risk stage III melanoma.
The FDA has granted a priority review to a supplemental new drug application for ibrutinib for use in combination with rituximab as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.
Bert H. O’Neil, MD, discusses the prevalence of neuroendocrine tumors and the agents that are used to treat patients who present with them.
Sai-Hong Ignatius Ou, MD, PhD, discusses the current landscapes of ROS1-positive and BRAF-mutant non–small cell lung cancer.
Ruxolitinib combined with corticosteroids induced an overall response rate of 55% at day 28 in patients with steroid-refractory acute graft-versus-host disease, meeting the primary endpoint of the phase II REACH1 trial.
Toby Eyre, MBChB, MRCP, discusses the results of the phase I study with venetoclax in patients with poor-risk relapsed/refractory mantle cell lymphoma.
Tanios Bekaii-Saab, MD, outlines clinical trials that have defined the current landscape of metastatic colorectal cancer and what research is underway.
The FDA has accepted a supplemental biologics license application for the combination of nivolumab plus ipilimumab for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.
The HER2-targeting antibody-drug conjugate (vic-)trastuzumab duocarmazine (SYD985) showed promising clinical activity in heavily-pretreated women with metastatic breast cancer.
Max Wicha, MD, shares insight on the intriguing research being conducted on breast cancer stem cells.
Zahi Mitri, MD, discusses adjuvant advances and other emerging trends in the treatment of patients with HER2-positive breast cancer.
Michael Simon, MD, MPH, discusses advances in genetic testing for breast cancer, highlighting the overlap between genomic risk assessment and tumor genomic profiling.
The FDA has incorporated PD-L1 status into the labels for pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for existing frontline approvals for platinum-ineligible patients with urothelial carcinoma.
